You are viewing the site in preview mode
Skip to main content
| |
Sepsis-2
|
Sepsis-3
|
Sepsis-2 and sepsis-3
|
Sepsis-2 and no sepsis-3
|
No sepsis-2 and sepsis-3
|
No sepsis-2 and no sepsis-3
|
|---|
|
Variables
| |
n = 530
|
n = 569
|
n = 501
|
n = 29
|
n = 68
|
n = 20
|
|---|
|
Microbiology of blood cultures
|
|
Gram-negative
|
E. coli
|
84 (15.9)
|
89 (15.6)
|
84 (16.8)
|
0
|
5 (7.4)
|
0
|
| |
Klebsiella
|
35 (6.6)
|
34 (6.0)
|
34 (6.8)
|
1 (3.5)
|
0
|
1 (5.0)
|
| |
Pseudomonas
|
2 (0.4)
|
2 (0.4)
|
2 (0.4)
|
0
|
0
|
0
|
|
Gram-positive
|
Staphylococci
|
62 (11.7)
|
66 (11.6)
|
60 (12.0)
|
2 (6.9)
|
6 (8.8)
|
0
|
| |
Streptococci
|
43 (8.1)
|
45 (7.9)
|
42 (8.4)
|
1 (3.5)
|
3 (4.4)
|
1 (5.0)
|
| |
MRSA
|
5 (0.9)
|
6 (1.1)
|
5 (1.0)
|
0
|
1 (1.5)
|
0
|
| |
Enterococcus
|
12 (2.3)
|
12 (2.1)
|
12 (2.4)
|
0
|
0
|
0
|
| |
Anaerobic
|
14 (2.6)
|
12 (2.1)
|
12 (2.4)
|
2 (6.9)
|
0
|
0
|
|
Fungi
| |
2 (0.4)
|
2 (0.4)
|
2 (0.4)
|
0
|
0
|
0
|
|
Antibiotics
|
|
Penicillin derivative (PCG, ABPC, ABPC/MCIPC)
| |
21 (4.0)
|
27 (4.8)
|
21 (4.2)
|
0
|
6 (8.8)
|
1 (5.0)
|
|
Ampicillin/sulbactam
| |
69 (13.0)
|
77 (13.5)
|
66 (13.2)
|
3 (10.3)
|
11 (16.2)
|
7 (35.0)
|
|
PIPC/TAZ
| |
73 (13.8)
|
73 (12.8)
|
64 (12.8)
|
9 (31.0)
|
9 (13.2)
|
6 (30.0)
|
|
First generation cephalosporin
| |
11 (2.1)
|
11 (2.0)
|
9 (1.8)
|
2 (6.9)
|
2 (2.9)
|
3 (15.0)
|
|
Second generation cephalosporin (CTM, CMZ, FMOX)
| |
13 (2.5)
|
17 (3.0)
|
11 (2.2)
|
2 (6.9)
|
6 (8.8)
|
0
|
|
Third generation cephalosporin (CTX, CPZ, CTRX)
| |
60 (11.3)
|
67 (11.8)
|
57 (11.4)
|
3 (10.3)
|
10 (14.7)
|
1 (5.0)
|
|
Third generation cephalosporin against pseudomonas
| |
3 (0.6)
|
3 (0.5)
|
3 (0.6)
|
0
|
0
|
0
|
|
Fourth generation cephalosporin against pseudomonas
| |
30 (5.7)
|
29 (5.1)
|
29 (5.8)
|
1 (3.5)
|
0
|
0
|
|
Carbapenem
| |
279 (52.6)
|
291 (51.1)
|
268 (53.5)
|
11 (37.9)
|
23 (33.8)
|
3 (15.0)
|
|
Aminoglycoside
| |
0
|
0
|
0
|
0
|
0
|
0
|
|
Quinolone
| |
32 (6.0)
|
35 (6.2)
|
32 (6.4)
|
0
|
3 (4.4)
|
0
|
|
Tetracycline
| |
3 (0.6)
|
3 (0.5)
|
3 (0.6)
|
0
|
0
|
0
|
|
Macrolide
| |
29 (5.5)
|
29 (5.1)
|
29 (5.8)
|
0
|
0
|
0
|
|
Metronidazole
| |
18 (3.4)
|
18 (3.2)
|
18 (3.6)
|
0
|
0
|
0
|
|
CLDM
| |
23 (4.3)
|
24 (4.2)
|
20 (4.0)
|
3 (10.3)
|
4 (5.9)
|
1 (5.0)
|
|
Vancomycin
| |
81 (15.3)
|
80 (14.1)
|
75 (15.0)
|
6 (20.7)
|
5 (7.4)
|
4 (20.0)
|
|
Other anti–methicillin-resistant staphylococcus aureus drugs
| |
45 (8.5)
|
48 (8.4)
|
45 (9.0)
|
0
|
3 (4.4)
|
0
|
|
Antifungus
| |
28 (5.3)
|
30 (5.3)
|
28 (5.6)
|
0
|
2 (2.9)
|
1 (5.0)
|
|
Others (ST, CLL, FOM, SBT/CPZ, AMPC)
| |
10 (1.9)
|
11 (1.9)
|
10 (2.0)
|
0
|
1 (1.5)
|
1 (5.0)
|
- Reported counts (proportions)
- ICU intensive care unit, PCG penicillin G, ABPC ampicillin, ABPC/MCIPC ampicillin/cloxacillin, PIPC/TAZ tazobactam/piperacillin, CTM cefotiam, CMZ cefmetazole, FMOX flomoxef, CTX cefotaxime, CPZ cefoperazone, CTRX ceftriaxone, CLDM clindamycin, ST sulfamethoxazole-trimethoprim, CLL cefaclor, FOM fosfomycin, SBT/CPZ sulbactam/cefoperazone, AMPC amoxicillin, MRSA methicillin-resistant Staphylococcus aureus
